US 11,897,930 B2
Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
Fan Ye, Mountain View, CA (US); Eric Liao, San Francisco, CA (US); Ella Li, San Francisco, CA (US); Matthew Siegel, Menlo Park, CA (US); Jianing Huang, San Mateo, CA (US); and Ziyang Zhong, Belmont, CA (US)
Assigned to Anwita Biosciences, Inc., San Carlos, CA (US)
Filed by Anwita Biosciences, Inc., San Carlos, CA (US)
Filed on Apr. 27, 2021, as Appl. No. 17/241,074.
Claims priority of provisional application 63/047,867, filed on Jul. 2, 2020.
Claims priority of provisional application 63/027,929, filed on May 20, 2020.
Claims priority of provisional application 63/016,289, filed on Apr. 28, 2020.
Prior Publication US 2021/0340208 A1, Nov. 4, 2021
Int. Cl. C07K 14/55 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/55 (2013.01) [A61K 38/00 (2013.01); C07K 2319/31 (2013.01); C07K 2319/33 (2013.01)] 28 Claims
 
1. An interleukin-2 polypeptide comprising an amino acid sequence of SEQ ID NO: 1, 2, 3, 4, or 5, wherein the interleukin-2 polypeptide comprises a replacement of the amino acid residues from positions 29 to 50 as set forth in SEQ ID NO: 1, 2, 3, 4, or 5 with a peptide comprising the amino acid sequence of an IL-15 hinge or a fragment thereof.